Compugen Pockets $3.6M from Evogene Share Sale | GenomeWeb

NEW YORK (GenomeWeb News) – Compugen has sold nearly half of its stake in Evogene, pocketing around $3.6 million from the share sale, the Tel Aviv, Israel-based firm said today.

Compugen said that it sold one million shares in a private transaction to a single, unidentified purchaser. It said that proceeds from the sale would be used to fund general corporate purposes through mid-2010.

Following the sale, Compugen holds 1,150,000 shares of Evogene, which uses Compugen's in silico predictive discovery capabilities for agricultural applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.